Purpose: To compare digital mammography (DM) plus digital breast tomosynthesis (DBT) versus DM alone for breast cancer screening in the Reggio Emilia Tomosynthesis trial, a two-arm test-and-treat randomized controlled trial.
B
reast cancer screening is an evidence-based intervention able to reduce mortality for breast cancer (1, 2) . However, mammography sensitivity is not optimal, and this limits screening efficacy (3) . Digital breast tomosynthesis (DBT) is an imaging technology that provides a three-dimensional reconstruction of the breast from a limited angle scan involving a series of low-dose mammographic exposures (4) .
In studies comparing both technologies in the same women, DBT has proven to be more sensitive than digital mammography (DM) in detecting cancers (5) (6) (7) (8) (9) . On the other hand, the relative specificity of DBT versus DM varies in different studies, mostly according to DM specificity (7, 8, 10, 11) . This makes DBT a very promising technology for screening. The U.S. Food and Drug Administration approved DBT as an adjunct to DM or synthetic twodimensional mammography (12) for screening; this combination has now been adopted in many screening facilities in the United States (13) . Nevertheless, the benefits and harms of this preventive intervention are delicately balanced (1) . In fact, being more sensitive is not always an advantage and may not always lead to a relevant impact on prognosis; screening can reveal cancers that will never be clinically relevant (overdiagnosis), or early diagnosis may not change prognosis. Thus, the European Commission makes cautious recommendations about DBT in screening (2) , and the American Cancer Society (14) and the U.S. Preventive Service Task Force (15) recommend further research. To test whether adding DBT to DM in screening is more effective than DM alone in improving prognosis and, possibly, in reducing mortality and morbidity, a randomized trial must be conducted in which women screened with DM are treated only according to the DM results, while women in the experimental arm are treated according to the DBT and DM results.
Nevertheless, data also on relative sensitivity and recall rate, reading time, and radiation dose are necessary to Digital Mammography versus Digital Mammography Plus Tomosynthesis for Breast Cancer Screening: The Reggio Emilia Tomosynthesis Randomized Trial guide the research on DBT and to predict the possible impact of introducing it in screening programs.
The Reggio Emilia Tomosynthesis trial (RETomo) was a twoarm test-and-treat randomized trial comparing DM+DBT versus DM in screening. Interval cancers and cumulative incidence of advanced cancers will be the main end points. In this preplanned interim analysis on half of the planned sample size, we compared the cancer detection rate, the recall rate, the time spent reading the screening test, and the radiation dose at baseline in women randomized to be screened either with DBT+DM or with DM.
Materials and Methods

Ethical Approval
Our randomized trial was approved by the provincial Ethical Committee (November 11, 2013; ASMN 2013/0029304), was partially funded by the Regione Emilia-Romagna, and was sustained by the institutional funds of the Reggio Emilia Local Health Authority-IRCCS. GE Healthcare (Buc, France) loaned one piece of tomosynthesis equipment for our study period; the support of GE Healthcare in our study was unconditional and was approved after the definition of the protocol. GE Healthcare had no role in the study design, data collection, analysis and interpretation, or writing of this report. The Reggio Emilia Local Health Authority is the data owner and has the full responsibility for publishing data. All participants signed a written informed consent form. The trial has been registered at clinicaltrials.gov as NCT02698202.
Setting
The province of Reggio Emilia, located in northern Italy, has a population of around 550 000. The population-based breast cancer screening program has been active since 1999. The target population includes women aged 45-74 years who are actively invited by the screening program with a fixed appointment call and recall system. The screening interval is 1 year for women aged 45-49 years and 2 years for women aged 50-74 years. The overall participation rate is 79%; for women who had previously participated, participation is 93% (16) . Mammogram readings for the six provincial mammography centers are centralized and performed by 10 radiologists whose screening experience ranges from 4 to 20 years (Table E1 [online]). All fulfill the regional screening quality assurance criterion of at least 5000 mammograms read per year and participate in periodic audits reviewing individual performance indicators and interval cancer imaging review. DBT was introduced 18 months before the start of the trial and was used for all symptomatic women and assessment. All screening mammograms are obtained with 11 GE Senographe Essential digital systems (GE Healthcare, Buc, France), four of which are equipped with tomosynthesis.
Study Design
This is a two-arm test-and-treat prospective randomized trial comparing DM+DBT versus DM alone. Women were randomized to undergo DM+DBT or DM alone at baseline. Both arms will be screened with DM in future rounds. The study began recruiting in March 2014; the end of recruitment was planned for December 2016 but was extended to July 2017. Here we report preliminary baseline results for women recruited from March 2014 to March 2016.
The main end points are interval cancers and cumulative incidence of advanced cancers (20 mm diameter) in the 4.5 years after recruitment. The 4.5-year follow up will permit the inclusion of all interval and screening-detected cancers of at least two rounds after recruitment. Furthermore, given that women allocated in both arms will be screened with DM in following rounds, our study design allows measuring the excess overdiagnosis comparing cumulative incidence of all cancers in the two arms. Our hypothesis is that the increase in lead time given by tomosynthesis is less than or equal to 4 years, a plausible hypothesis given that the estimated lead time in mammographic screening is from 3 to 4 years (17) . A similar study design for the introduction of a screening test with greater sensitivity was used in many trials about human papillomavirus testing for cervical cancer screening (18) .
In our preplanned interim analysis, we report baseline detection and recall rate data in half of the planned sample size. Data on dose and reading time are also reported.
Inclusion Criteria and Randomization Procedures
Women aged 45 to 70 years attending screening in one of three clinics equipped with DBT and who had already participated in at least one round of the Reggio Emilia screening program were eligible. Women with previous breast cancer, prior DBT, and ascertained genetic risk for breast cancer (based on a standardized risk score used by the regional screening program) were identified through analysis of the local screening program database and were automatically excluded. During the screening visit, women were also excluded if they had very large breasts, which could require more than one exposure for each projection, a familial risk score update due to recent breast cancer in relatives, augmentation prostheses, or pregnancy or for technical reasons (eg, randomization procedure or DBT was Abbreviations CI = confidence interval, BI-RADS = Breast Imaging and Reporting Data System, DBT = digital breast tomosynthesis, DCIS = ductal carcinoma in situ, DM = digital mammography, HER2 = human epidermal growth factor receptor 2, IQR = interquartile range, PPV = positive predictive value
Summary
Tomosynthesis plus digital mammography detects 90% more cancers than digital mammography alone, with similar recall rate. This higher detection may have a beneficial impact on cancer prognosis.
Implication for Patient Care
n Tomosynthesis plus digital mammography depicts more cancers than digital mammography alone. Only data on following screening rounds can say to what extent this higher detection rate has an impact on cancer prognosis and reveal the effects of digital breast tomosynthesis on overdiagnosis compared with digital mammography.
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arbitration) out of the total number of screened women. Dose per projection was directly measured by the machine. Reading time was automatically registered by the information system.
Sample Size and Study Power
Sample size was estimated as 40 000 women (20 000 per arm) according to feasibility constraints (ie, recruitment time and overall target population). The power was calculated assuming an incidence rate of interval cancers of two per 1000 women screened (21) in the control group; a sample of 40 000 women would allow a power of 73% to observe a decrease in interval breast cancers of at least 50%, accepting a 5% probability of a error with a x 2 test. For advanced breast cancers, assuming a cumulative incidence of three per 1000 women screened in 4 years in the control group (data from local cancer registry and screening registry linkage), the sample size gave a power of 89% to observe a decrease of at least 50% with a 5% probability of a error. Our study was powered on the main end points; as the power was much higher for the baseline end points, interim analyses at 20 000 recruited women were preplanned to give statistically stable results on relevant screening outcomes.
Statistical Analysis
All comparisons between experimental and control arm were according to intention to treat. Ninety-five percent confidence intervals (CIs) for both relative and absolute effect measures were calculated according to exact binomial distribution. Positive predictive value (PPV), also called PPV1, was calculated as all cancers found in the total number of recalled women (22) . False-positive results are defined the absence of cancer in recalled women. We tested the interaction between study arm and age (in three groups: 45-49 years, 50-59 years, and 60-70 years) using the likelihood ratio test, comparing the model with and without interaction term.
We present Cohen k values for the concordance between the two readers for the dichotomous classification of positive or negative (23) . Furthermore, we computed the relative sensitivity for both readers and for at least one reader of DBT alone compared with DBT+DM (in the same arm). It must be considered that if the positivity at DBT was not confirmed at DBT+DM, the woman was not recalled for assessment; therefore, the sensitivity of DBT alone is systematically underestimated. Analyses of DBT-alone reading were performed in the restricted population of women who actually underwent a full DBT examination.
Medians and interquartile ranges (IQRs) are reported for dose per examination (four projections) and for reading time. P values for equal median time were calculated with the nonparametric test. All analyses were performed with Stata, version 13.0 (2013) statistical software (Stata, College Station, Tex).
Results
The acceptance rate was 62.9%, with 9777 women randomized to the experimental arm and 9783 to the control arm; 115 women randomized to the experimental arm underwent DM only or incomplete DBT projections (Fig 1) . Age was balanced temporarily unavailable). Women who fit any of these criteria were excluded onsite before we proposed our study, and standard DM was performed.
At the moment of the screening test, the radiographer gave information about our study to eligible women, then performed standard digital mammography. After completing the four DM projections, the women who declared their interest in our study were asked to confirm participation and to sign a written informed consent form. The whole eligible pool of women was randomized and allocated to one of the arms through a pseudo-random number generator by the screening coordinating center. Information about randomization and allocation was stored in a hidden variable not accessible to anyone until the woman confirmed and signed her consent form; at that moment, the allocation was disclosed. Violation of allocation protocol was impossible for the control arm. In a few procedures, it was impossible to perform DBT in women randomized to the experimental arm because of technical reasons or the woman's refusal to undergo further compression. According to a strict intention-to-treat analysis, no exclusion after a disclosure of randomization was allowed, and outcomes of women allocated to one arm were considered as results of the assigned intervention independently from the actual procedure undergone.
Interventions DM and DBT in the two study arms were all performed with the same machines. All women underwent standard two-projection (craniocaudal plus mediolateral oblique) mammography, and mammograms were independently read by two radiologists; in cases of disagreement, arbitration by a third reader was conclusive, as for routine screening.
In the experimental arm, the radiologist read the DBT study in sequence, scrolling continuously from slabs (1-cm thickness, 0.5-cm overlap) to sections 1 mm thick, and gave a judgment of positive or negative; the workstation then presented DM together with previous mammograms. The radiologist made the final decision at this step. Breast density according to the Breast Imaging and Reporting Data System (BI-RADS) (19) was recorded only for recalled women (see Appendix E1 [online] for details).
In the experimental arm, arbitration made decisions only on the DBT+DM study, including previous mammograms. Women with positive or suspicious screening results were recalled for imaging assessment and for biopsy when necessary (see Appendix E1 [online]).
Outcome Ascertainment
All cancers diagnosed up to 9 months from recruitment in recalled women were included in the analyses to include women with 6-month early recall after inconclusive assessment. Lesions were classified according to maximum dimension, stage, grade, hormone receptor positivity, and human epidermal growth factor receptor 2 (HER2) and Ki67 positivity (see Appendix E1 [online] for details) (20) .
Recall rate was defined as the proportion of women recalled for further assessment (after double reading and radiology.rsna.org n Radiology: Volume 288: Number 2-August 2018 was similar for both cancers smaller than 10 mm and cancers between 10 and 20 mm, while there was no gain in the detection for larger cancers. The same was true for grade, where the gain was only for grade 1 and 2 cancers but not for grade 3 cancers (Table 3 ). The gain in detection was also noticeable for stage II cancers, although the numbers were small and the 95% CI included 1. The gain was more evident in all the more favorable classes of molecular biomarkers. Finally, the gain in detection was similar in all density classes, with a relative detection rate of 2.0, 2.1, 1.5, and 2.3 in BI-RADS density classes A, B, C, and D, respectively.
The concordance between the two readers was slightly higher for DM (k = 0.48) than for DBT alone (k = 0.37) or for DBT+DM (k = 0.43) ( Table 4) . Of the 80 cancers found in women with complete experimental procedures, 72 (90.0%) were positive at DBT alone for at least one of the two readers (Fig 2) . On the other hand, eight cancers, including six instances of DCIS, were found in the 53 women who had negative results at DBT for both readers but who were recalled during the DBT+DM reading (Fig 3) .
The median dose per examination was 6.40 mGy (IQR, 5.68.-7.36 mGy) and 4.84 mGy (IQR, 4.24-5.72 mGy) for DBT and DM, respectively, meaning that the dose in the experimental arm was 2.3 times higher than that in the control arm.
in the two arms: Mean age was 56.2 years versus 56.3 years in the experimental and control arms, respectively.
The recall rate was 3.5% in the two arms ( The ratio between surgery for benign lesions and surgery for malignant lesions was 0.11 in both arms, but there were slightly more women treated for benign lesions in the experimental arm (0.9 per 1000 vs 0.5 per 1000). A larger proportion of women in the DBT+DM arm than in the control arm were referred for early recall after the first assessment session (20.3% vs 11.5% of the women with recall), and nine and no cancers were found in early recalls in the DBT+DM and control arms, respectively.
The relative detection rates for DBT+DM versus DM alone were similar in all age groups, ranging from 1.83 to 2.04 (P = .93); the same was true for relative recall rate, which ranged from 0.93 to 1.11 (P = .52) ( Table 2 ). The gain in detection was higher for ductal carcinoma in situ (DCIS) (relative detection, 2.80 [95% CI: 1.01, 7.65]) than for invasive cancer. Among invasive cancers, the gain in detection (P , .01), while for recall decision, the reading times were 104 seconds (IQR, 70-150 seconds) and 114 seconds (IQR, 67-176 seconds), respectively (P = .54). Median reading time
In women with negative results, the median reading times for DM alone and DBT alone were 34 seconds (IQR, 23-51 seconds) and 56 seconds (IQR, 43-77 seconds), respectively Note.-Unless otherwise specified, data are numbers of women or cancers, with percentages in parentheses. DBT = digital breast tomosynthesis, DCIS = ductal carcinoma in situ, DM = digital mammography. Positive predictive value (PPV) (also called PPV1) was calculated as all cancers found in the total number of recalled women (21); P = .0002 for the difference between arms. * Data in parentheses are 95% confidence intervals. Relative risk was defined as the occurrence of an outcome in the experimental arm divided by the occurrence of the same outcome in the control arm. Risk difference was defined as the difference between the occurrence of an outcome out of 1000 screened women in the experimental arm and the occurrence of the same outcome out of 1000 screened women in the control arm. † Benign lesions included eight lesions of uncertain malignant potential and one benign lesion in the experimental arm; and one lobular intraepithelial lesion, three lesions of uncertain malignant potential, and one benign lesion in the control arm. ‡ A false-positive result occurred when a woman was recalled but did not have cancer. Note.-Unless otherwise specified, data are numbers of women or cancers, with percentages in parentheses. DBT = digital breast tomosynthesis, DM = digital mammography. * Data in parentheses are 95% confidence intervals. Relative risk was defined as the occurrence of an outcome in the experimental arm divided by the occurrence of the same outcome in the control arm. Risk difference was defined as the difference between the occurrence of an outcome out of 1000 screened women in the experimental arm and the occurrence of the same outcome out of 1000 screened women in the control arm. † PPV (positive predictive value), also called PPV1, was calculated as all cancers found in the total number of recalled women (21) . ‡ A false-positive result occurred when a woman was recalled but did not have cancer.
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in detection rate observed in our study is slightly higher than in previous European studies (ranging from +30% to +50%) (7-9,13) and is substoantially higher than in U.S. observational studies (13, (24) (25) (26) . There are several possible explanations for this difference. First, our study population did not include women in their first round of screening or women with familial risk, thus reducing the overall detection rate and esperanged among the readers from 20 to 58 seconds for DM alone and from 35 to 81 seconds for DBT alone.
Discussion
In our study the detection rate was about 90% higher with DBT+DM than with DM alone (8.6 per 1000 women screened vs 4.5 per 1000, respectively), with similar recall rates. The gain Note.-Unless otherwise noted, data are numbers of women or lesions. Data in parentheses are 95% confidence intervals. BI-RADS = Breast Imaging Reporting and Data System, DBT = digital breast tomosynthesis, DCIS = ductal carcinoma in situ, DM = digital mammography, HER2 = human epidermal growth factor receptor, NA = not available. * Relative risk was defined as the occurrence of an outcome in the experimental arm divided by the occurrence of the same outcome in the control arm. Risk difference was defined as the difference between the occurrence of an outcome out of 1000 screened women in the experimental arm and the occurrence of the same outcome out of 1000 screened women in the control arm. for an increase in overdiagnosis of non-clinically relevant lesions. Furthermore, we detected more instances of DCIS (+1 per 1000) and slightly more benign lesions and lesions of uncertain malignant potential referred for excision in the experimental arm (+0.5 per 1000). Previous studies did not find a higher relative sensitivity for DCIS than for invasive cancers with DBT (5) (6) (7) 11, 24, 30) . Surprisingly, six of 14 instances of DCIS in our experimental arm were found in women who had negative results at both DBT readings and positive results at at least one DBT+DM reading. An analysis of the DBT images of these six instances of DCIS revealed that some abnormalities-in particular, four microcalcifications and two masses with regular margins-were visible, but these findings were judged as not clinically relevant in the absence of previous mammograms. Only when the DM study with the comparison of previous mammograms was evaluated did the evolving nature of the lesions appear clear, acquiring clinical relevance for the radiologist. The role of DCIS detection in screening has been questioned, with some authors suggesting that this is one of the major sources of overdiagnosis (30) . Nevertheless, the role of DCIS as a precursor of invasive cancers has been clearly shown (31) . Furthermore, the association between screening sensitivity for DCIS and subsequent reduction in invasive cancer incidence has been shown in a recent observational study (32) in the United Kingdom. Our DCIS detection rate of 1.4 per 1000 is within the threshold that could be beneficial, with about 1.5-3.0 instances of DCIS needed to treat to prevent one invasive cancer (33) .
The dose in the experimental arm was 2.3 times higher than that in the control arm; using DBT alone could avoid double exposure. In fact, most of the gain in invasive cancer detection observed in the experimental arm was due to DBT alone. The same was observed in previous studies (5) .
cially the prevalence of large lesions, which are easily detected also at DM alone. Moreover, the randomized design ruled out any contamination of the control arm. Finally, we cannot rule out that DM sensitivity in our screening program was lower than that in previous studies. However, this last hypothesis is not consistent with the good performance of the Reggio Emilia screening program in terms of interval cancer incidence and routine detection rate monitoring (27, 28) .
Recall rate was almost identical in the two arms and was in line with European screening program performance indicators (28) ; previous studies have observed both an increase (7, 10, 11) and a decrease compared with DM (8, (24) (25) (26) , which is not surprising because DM specificity varies between countries and between screening centers within countries, depending on the program requirements, the enforcement of these requirements, and on the radiologists' approach. Nevertheless, we confirm that the recall rate for DBT is more stable across studies than that for DM (29) .
We observed a lower agreement between readers for DBT alone and, less markedly, for DBT+DM compared with DM. Given the similar overall recall rate, this means that the number of women judged as having positive results by each reader was lower for DBT than for DM, which promises further improvement of DBT specificity once criteria for positivity are harmonized.
Potential Harms
The gain in detection was observed for all classes except very large or late cancers (cancers  20 mm, grade 3 cancers, and estrogen-and progesterone-receptor-negative and HER2-positive cancers). These characteristics, together with the magnitude of the gain in detection, suggest that early cancer diagnosis is occurring. This is promising in terms of the impact on prognosis and ultimately on mortality but also leaves room (7, 33, 34) . Absolute differences were actually smaller than those observed in experimental studies. Differences almost disappeared when the DBT study was judged positive, suggesting that the longer time was mostly due to the longer approach to the multiple images and not to a longer time in the interpretation of findings. Variability between readers was high but was almost the same in both arms. If the variability in DM is still that high after years of training and practice, then it will not be easy to bring the slowest readers up to the times of the fastest ones with DBT. The sustainability of introducing DBT in routine screening programs depends on how much reading times can be reduced.
However, this strategy has a limit during the first round of DBT screening (ie, when prior mammograms were twodimensional [2D] only), as evaluating the evolution of the lesion over time is impossible. The use of synthetic 2D also eliminates the double exposure, but specificity could be still suboptimal (11) .
Reading Times
The reading time of DBT was about 70% longer than that of DM. Our results show a relative increase in time similar to that obtained in previous studies, ranging from more than 100% to 50% longer, mostly depending on how fast the DM reading was could not apply the standard procedure of arbitration for discordant readings. About 37% of eligible women refused to participate in our study. We cannot assess whether these women had different
Limitations
We cannot consider as real-practice results those observed for the DBT-alone readings because the readers knew that these judgements were not used for the women's care; therefore, we characteristics compared with nonparticipating women, but it is possible. In the 49 women who had problems completing DBT, mostly because of compression discomfort, we found two cancers, which was more than expected. Nevertheless, the strict intention-to-treat analysis should avoid any bias affecting internal validity.
Our study's reading workflow permitted an accurate realpractice estimate of DM and DBT reading time, but it did not allow a measurement of the DBT+DM reading time, as this occurred after reading DBT alone.
Conclusions DBT+DM depicts about 90% more cancers in a population previously screened with DM, with a similar recall rate. The gain in detection is appreciable for all cancers up to 19 mm in diameter and stage II. Only data on following screening rounds can say to what extent this higher detection rate has an impact on cancer prognosis and what the effects of DBT are on overdiagnosis compared with digital mammography.
